-
Mashup Score: 0Adnexal lesions: Preoperative assessment - 8 hour(s) ago
The ENYGO Podcast · Episode
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer - 6 day(s) ago
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II LITESPARK-029 trial (NCT06428396) of belzutifan, a HIF-2α inhibitor, with fulvestrant versus everolimus with fulvestrant or exemestane in patients with ER+/HER2- unresectable or metastatic breast cancer. Primary endpoints include progression-free survival (PFS) and secondary objectives include overall survival and clinical benefit. This trial aims to address resistance mechanisms and improve outcomes in advanced disease. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome - 6 day(s) ago
Background Pathogenic germline variants in the mismatch repair (MMR) genes are associated with an increased risk of prostate cancer (PCa). Since 2010 we have recommended MMR carriers annual PSA test…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome - 8 day(s) ago
Background Pathogenic germline variants in the mismatch repair (MMR) genes are associated with an increased risk of prostate cancer (PCa). Since 2010 we have recommended MMR carriers annual PSA test…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in Triple-Negative Breast Cancer - 10 day(s) ago
This phase 3 randomized clinical trial examines the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with triple-negative breast cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer - 11 day(s) ago
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer - 11 day(s) ago
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases | JCO Global Oncology - 12 day(s) ago
PURPOSEThis manuscript reports the results of the Indian Network for Development of Peritoneal Surface Oncology and Indian Society of Peritoneal Surface Malignancies (INDEPSO-ISPSM) consensus that aimed to provide recommendations for some important …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Emotional impact of cancer from a patient's perspective - 12 day(s) ago
Your work in geriatric oncology places you in a unique position to help people in the most significant way possible–to literally save their lives. Such a duty of care is profound, perhaps even more so when you face the most vulnerable patients– including children, the underprivileged, or those diminished by prior illness or the aging process itself.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
RT @ArturasDobilas: Thanks👏 @OncoAlert @nsgo_org @ESGO_society https://t.co/qqW9TgyjOx